Exabis Library
Welcome to the e-CCO Library!
DOP60: Self-reported treatment effectiveness for Crohn's Disease using a novel crowdsourcing web-based platform
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP60: Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study data
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP60: The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non-response in Crohn’s
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP60: Vedolizumab treatment persistence and safety in an extended access program (XAP)
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP60: Vedolizumab treatment persistence and safety in an extended access program (XAP)
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP61: A nationwide cohort study of colectomy rates for ulcerative colitis during the introduction of biologic therapy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP61: A nationwide cohort study of colectomy rates for ulcerative colitis during the introduction of biologic therapy
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP61: Development and validation of novel models in prediction of intravenous corticosteroids resistance in patients with Acute Severe Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP61: Ethnic disparities in the management of Inflammatory Bowel Disease in Israel and impact on outcomes
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP61: Ethnic disparities in the management of Inflammatory Bowel Disease in Israel and impact on outcomes
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP61: Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP61: Tofacitinib, an oral, small molecule Janus kinase inhibitor, in the treatment of Ulcerative Colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP61: Tofacitinib, an oral, small molecule Janus kinase inhibitor, in the treatment of Ulcerative Colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP61: Up-regulated Gremlin 1 in fibroblasts from Crohn’s Disease fibrotic strictures: A potential therapeutic target
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP62 Morbidity after primary ileocecal resection for Crohn’s disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP62: A core molecular resistome characterised by extracellular matrix dysregulation and neutrophil degranulation predicts resistance to multiple therapies in Ulcerative Colitis
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP62: A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP62: A Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: 1-Year Result from a Phase I Open-label Randomised Controlled Trial in Patients with Active Crohn’s Disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP62: Efficacy of biologic drugs in short-duration versus long-duration Inflammatory Bowel Disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM